257 related articles for article (PubMed ID: 29278889)
1. Erythromyeloid-Derived TREM2: A Major Determinant of Alzheimer's Disease Pathology in Down Syndrome.
Raha-Chowdhury R; Henderson JW; Raha AA; Stott SRW; Vuono R; Foscarin S; Wilson L; Annus T; Fincham R; Allinson K; Devalia V; Friedland RP; Holland A; Zaman SH
J Alzheimers Dis; 2018; 61(3):1143-1162. PubMed ID: 29278889
[TBL] [Abstract][Full Text] [Related]
2. Triggering Receptor Expressed on Myeloid Cell 2 R47H Exacerbates Immune Response in Alzheimer's Disease Brain.
Korvatska O; Kiianitsa K; Ratushny A; Matsushita M; Beeman N; Chien WM; Satoh JI; Dorschner MO; Keene CD; Bammler TK; Bird TD; Raskind WH
Front Immunol; 2020; 11():559342. PubMed ID: 33101276
[TBL] [Abstract][Full Text] [Related]
3. Alzheimer's disease-associated R47H TREM2 increases, but wild-type TREM2 decreases, microglial phagocytosis of synaptosomes and neuronal loss.
Popescu AS; Butler CA; Allendorf DH; Piers TM; Mallach A; Roewe J; Reinhardt P; Cinti A; Redaelli L; Boudesco C; Pradier L; Pocock JM; Thornton P; Brown GC
Glia; 2023 Apr; 71(4):974-990. PubMed ID: 36480007
[TBL] [Abstract][Full Text] [Related]
4. TREM2 Alzheimer's variant R47H causes similar transcriptional dysregulation to knockout, yet only subtle functional phenotypes in human iPSC-derived macrophages.
Hall-Roberts H; Agarwal D; Obst J; Smith TB; Monzón-Sandoval J; Di Daniel E; Webber C; James WS; Mead E; Davis JB; Cowley SA
Alzheimers Res Ther; 2020 Nov; 12(1):151. PubMed ID: 33198789
[TBL] [Abstract][Full Text] [Related]
5. TNF-α-mediated reduction in inhibitory neurotransmission precedes sporadic Alzheimer's disease pathology in young Trem2
Ren S; Breuillaud L; Yao W; Yin T; Norris KA; Zehntner SP; D'Adamio L
J Biol Chem; 2021; 296():100089. PubMed ID: 33434745
[TBL] [Abstract][Full Text] [Related]
6. R47H TREM2 variant increases risk of typical early-onset Alzheimer's disease but not of prion or frontotemporal dementia.
Slattery CF; Beck JA; Harper L; Adamson G; Abdi Z; Uphill J; Campbell T; Druyeh R; Mahoney CJ; Rohrer JD; Kenny J; Lowe J; Leung KK; Barnes J; Clegg SL; Blair M; Nicholas JM; Guerreiro RJ; Rowe JB; Ponto C; Zerr I; Kretzschmar H; Gambetti P; Crutch SJ; Warren JD; Rossor MN; Fox NC; Collinge J; Schott JM; Mead S
Alzheimers Dement; 2014 Nov; 10(6):602-608.e4. PubMed ID: 25160042
[TBL] [Abstract][Full Text] [Related]
7. An Altered Relationship between Soluble TREM2 and Inflammatory Markers in Young Adults with Down Syndrome: A Preliminary Report.
Weber GE; Koenig KA; Khrestian M; Shao Y; Tuason ED; Gramm M; Lal D; Leverenz JB; Bekris LM
J Immunol; 2020 Mar; 204(5):1111-1118. PubMed ID: 31959733
[TBL] [Abstract][Full Text] [Related]
8. The triggering receptor expressed on myeloid cells 2 (TREM2) is associated with enhanced inflammation, neuropathological lesions and increased risk for Alzheimer's dementia.
Roussos P; Katsel P; Fam P; Tan W; Purohit DP; Haroutunian V
Alzheimers Dement; 2015 Oct; 11(10):1163-70. PubMed ID: 25499537
[TBL] [Abstract][Full Text] [Related]
9. SHIP inhibition mediates select TREM2-induced microglial functions.
Ramakrishnan GS; Berry WL; Pacherille A; Kerr WG; Chisholm JD; Pedicone C; Humphrey MB
Mol Immunol; 2024 Jun; 170():35-45. PubMed ID: 38613944
[TBL] [Abstract][Full Text] [Related]
10. A Trem2
Tran KM; Kawauchi S; Kramár EA; Rezaie N; Liang HY; Sakr JS; Gomez-Arboledas A; Arreola MA; Cunha CD; Phan J; Wang S; Collins S; Walker A; Shi KX; Neumann J; Filimban G; Shi Z; Milinkeviciute G; Javonillo DI; Tran K; Gantuz M; Forner S; Swarup V; Tenner AJ; LaFerla FM; Wood MA; Mortazavi A; MacGregor GR; Green KN
Mol Neurodegener; 2023 Feb; 18(1):12. PubMed ID: 36803190
[TBL] [Abstract][Full Text] [Related]
11. Impact of TREM2 risk variants on brain region-specific immune activation and plaque microenvironment in Alzheimer's disease patient brain samples.
Prokop S; Miller KR; Labra SR; Pitkin RM; Hoxha K; Narasimhan S; Changolkar L; Rosenbloom A; Lee VM; Trojanowski JQ
Acta Neuropathol; 2019 Oct; 138(4):613-630. PubMed ID: 31350575
[TBL] [Abstract][Full Text] [Related]
12. Microglial TREM2 at the Intersection of Brain Aging and Alzheimer's Disease.
Qu W; Li L
Neuroscientist; 2023 Jun; 29(3):302-316. PubMed ID: 34470515
[TBL] [Abstract][Full Text] [Related]
13. Neocortical and hippocampal TREM2 protein levels during the progression of Alzheimer's disease.
Perez SE; Nadeem M; He B; Miguel JC; Malek-Ahmadi MH; Chen K; Mufson EJ
Neurobiol Aging; 2017 Jun; 54():133-143. PubMed ID: 28365005
[TBL] [Abstract][Full Text] [Related]
14. Trem2 Y38C mutation and loss of Trem2 impairs neuronal synapses in adult mice.
Jadhav VS; Lin PBC; Pennington T; Di Prisco GV; Jannu AJ; Xu G; Moutinho M; Zhang J; Atwood BK; Puntambekar SS; Bissel SJ; Oblak AL; Landreth GE; Lamb BT
Mol Neurodegener; 2020 Oct; 15(1):62. PubMed ID: 33115519
[TBL] [Abstract][Full Text] [Related]
15. TREM2 variants in Alzheimer's disease.
Guerreiro R; Wojtas A; Bras J; Carrasquillo M; Rogaeva E; Majounie E; Cruchaga C; Sassi C; Kauwe JS; Younkin S; Hazrati L; Collinge J; Pocock J; Lashley T; Williams J; Lambert JC; Amouyel P; Goate A; Rademakers R; Morgan K; Powell J; St George-Hyslop P; Singleton A; Hardy J;
N Engl J Med; 2013 Jan; 368(2):117-27. PubMed ID: 23150934
[TBL] [Abstract][Full Text] [Related]
16. Expression of the phagocytosis-essential protein TREM2 is down-regulated by an aluminum-induced miRNA-34a in a murine microglial cell line.
Alexandrov PN; Zhao Y; Jones BM; Bhattacharjee S; Lukiw WJ
J Inorg Biochem; 2013 Nov; 128():267-9. PubMed ID: 23778113
[TBL] [Abstract][Full Text] [Related]
17. Identification of senescent, TREM2-expressing microglia in aging and Alzheimer's disease model mouse brain.
Rachmian N; Medina S; Cherqui U; Akiva H; Deitch D; Edilbi D; Croese T; Salame TM; Ramos JMP; Cahalon L; Krizhanovsky V; Schwartz M
Nat Neurosci; 2024 Jun; 27(6):1116-1124. PubMed ID: 38637622
[TBL] [Abstract][Full Text] [Related]
18. Developmental deficits and staging of dynamics of age associated Alzheimer's disease neurodegeneration and neuronal loss in subjects with Down syndrome.
Wegiel J; Flory M; Kuchna I; Nowicki K; Wegiel J; Ma SY; Zhong N; Bobrowicz TW; de Leon M; Lai F; Silverman WP; Wisniewski T
Acta Neuropathol Commun; 2022 Jan; 10(1):2. PubMed ID: 34983655
[TBL] [Abstract][Full Text] [Related]
19. TREM2 splice isoforms generate soluble TREM2 species that disrupt long-term potentiation.
Moutinho M; Coronel I; Tsai AP; Di Prisco GV; Pennington T; Atwood BK; Puntambekar SS; Smith DC; Martinez P; Han S; Lee Y; Lasagna-Reeves CA; Lamb BT; Bissel SJ; Nho K; Landreth GE
Genome Med; 2023 Feb; 15(1):11. PubMed ID: 36805764
[TBL] [Abstract][Full Text] [Related]
20. Stimulation of TREM2 with agonistic antibodies-an emerging therapeutic option for Alzheimer's disease.
Schlepckow K; Morenas-Rodríguez E; Hong S; Haass C
Lancet Neurol; 2023 Nov; 22(11):1048-1060. PubMed ID: 37863592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
